Saturday 17 October 2026
Export CGTX’s income statement to Excel — free account
Cognition Therapeutics, Inc.
CGTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.6% and free cash flow grew 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.73
0.00
0.00%
Follow CGTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(109.73%) | (88.60%) | (92.82%) | (83.76%) | |
| (78.86%) | (59.75%) | (65.65%) | (57.33%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(76.91%) | (68.76%) | (65.61%) | (50.93%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.38) | (0.34) | (0.23) | (0.20) | |
Free Cash Flow |
(29.53) | (24.58) | (20.25) | (17.69) | |
Capital Expenditures |
— | 0.01 | — | (0.01) | |
| Other line items | |||||
Cash ROIC |
(38.68%) | (34.49%) | (33.13%) | (26.10%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | (1,911.96) | (2,380.06) | (2,287.56) | |
Operating CF/Net income |
1.06 | 1.05 | 1.03 | 1.05 | |
Depreciation/Fixed assets |
1.50 | 2.45 | 3.26 | 2.82 | |
Capex/Depreciation |
0.00 | 0.02 | 0.00 | (0.05) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.38) | (0.34) | (0.23) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | 0.00 |
Columns are period end dates